Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Rankning i aktier #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Aktiekurs
$0.11725176
Senast synkroniserad: 2025-07-14
Marknadsvärde
$481.50K
Förändring (1 dag)
-0.20%
Förändring (1 år)
0.00%
Land
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)

Kategori

P/B-tal för PHAXIAM Therapeutics S.A. (PHXM)
P/B-tal per August 2026 TTM: 0.02
Enligt PHAXIAM Therapeutics S.A. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) 0.02. I slutet av 2022 hade företaget ett P/B-tal på 0.48.
Historik för P/B-tal för PHAXIAM Therapeutics S.A. från 2016 till 2026
P/B-tal vid årets slut
År P/B-tal Ändra
2026 (TTM) 0.02 -97.64%
2023 0.78 60.84%
2022 0.48 -77.96%
2021 2.20 -55.37%
2020 4.93 250.70%
2019 1.40 82.40%
2018 0.77 -33.59%
2017 1.16 -62.33%
2016 3.08 0.00%
P/B-tal för liknande företag eller konkurrenter
Företag P/B-tal Skillnad i P/B-tal Land
6.2613 33,928.80%
US
6.3483 34,401.63%
NL
- -
CH
- -
KR
3.634 19,650.00%
BE